According to Precedence Research, the global mice model market size will grow from USD 11.43 billion in 2025 to nearly USD 19 ...
Monash University researchers used CRISPR or a PTPN2 inhibitor to enhance CAR T cell function against solid tumors. Blocking ...
Advances in genome editing have transformed the development of animal models used to understand human diseases. While transgenic mouse models have broadly ...
A research team drawn from Arc Institute, the University of California San Francisco, and the Fred Hutchinson Cancer Center, ...
CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...
This session presents two linked talks on CRISPR–Cas9 model generation and sequence validation. Christopher Raymond will discuss how direct zygote editing in mice and rats reduces timelines and costs ...
A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers.
Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback